- Home
- UHG vs FHTX Comparison
UHG vs FHTX Comparison
Compare UHG & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- FHTX
- Stock Information
- Founded
- UHG 2004
- FHTX 2015
- Country
- UHG United States
- FHTX United States
- Employees
- UHG N/A
- FHTX N/A
- Industry
- UHG Homebuilding
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- UHG Consumer Discretionary
- FHTX Health Care
- Exchange
- UHG Nasdaq
- FHTX Nasdaq
- Market Cap
- UHG 253.1M
- FHTX 237.4M
- IPO Year
- UHG N/A
- FHTX 2020
- Fundamental
- Price
- UHG $4.11
- FHTX $4.08
- Analyst Decision
- UHG
- FHTX Strong Buy
- Analyst Count
- UHG 0
- FHTX 6
- Target Price
- UHG N/A
- FHTX $13.17
- AVG Volume (30 Days)
- UHG 78.3K
- FHTX 110.9K
- Earning Date
- UHG 03-13-2025
- FHTX 03-06-2025
- Dividend Yield
- UHG N/A
- FHTX N/A
- EPS Growth
- UHG N/A
- FHTX N/A
- EPS
- UHG N/A
- FHTX N/A
- Revenue
- UHG $445,729,916.00
- FHTX $25,515,000.00
- Revenue This Year
- UHG N/A
- FHTX N/A
- Revenue Next Year
- UHG N/A
- FHTX $7.37
- P/E Ratio
- UHG N/A
- FHTX N/A
- Revenue Growth
- UHG 6.19
- FHTX N/A
- 52 Week Low
- UHG $3.77
- FHTX $2.81
- 52 Week High
- UHG $7.83
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- UHG 40.72
- FHTX 34.51
- Support Level
- UHG $4.11
- FHTX $3.86
- Resistance Level
- UHG $4.81
- FHTX $4.64
- Average True Range (ATR)
- UHG 0.27
- FHTX 0.34
- MACD
- UHG 0.02
- FHTX 0.07
- Stochastic Oscillator
- UHG 11.25
- FHTX 15.38
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.